EMBO Molecular Medicine (Feb 2023)

A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein mediates immune function

  • Wael Bahnan,
  • Lotta Happonen,
  • Hamed Khakzad,
  • Vibha Kumra Ahnlide,
  • Therese deNeergaard,
  • Sebastian Wrighton,
  • Oscar André,
  • Eleni Bratanis,
  • Di Tang,
  • Thomas Hellmark,
  • Lars Björck,
  • Oonagh Shannon,
  • Lars Malmström,
  • Johan Malmström,
  • Pontus Nordenfelt

DOI
https://doi.org/10.15252/emmm.202216208
Journal volume & issue
Vol. 15, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Group A streptococci have evolved multiple strategies to evade human antibodies, making it challenging to create effective vaccines or antibody treatments. Here, we have generated antibodies derived from the memory B cells of an individual who had successfully cleared a group A streptococcal infection. The antibodies bind with high affinity in the central region of the surface‐bound M protein. Such antibodies are typically non‐opsonic. However, one antibody could effectively promote vital immune functions, including phagocytosis and in vivo protection. Remarkably, this antibody primarily interacts through a bivalent dual‐Fab cis mode, where the Fabs bind to two distinct epitopes in the M protein. The dual‐Fab cis‐binding phenomenon is conserved across different groups of M types. In contrast, other antibodies binding with normal single‐Fab mode to the same region cannot bypass the M protein's virulent effects. A broadly binding, protective monoclonal antibody could be a candidate for anti‐streptococcal therapy. Our findings highlight the concept of dual‐Fab cis binding as a means to access conserved, and normally non‐opsonic regions, regions for protective antibody targeting.

Keywords